Medicines and Healthcare products Regulatory Agency

CERTIFICATE NUMBER : UK API 36699 Insp GMP 36699/17092-0056

CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER*(1),(2)*

Part 1

Issued following an inspection in accordance with :
Regulation 331A of The Human Medicines Regulations 2012 (SI 2012/1916)

The competent authority of United Kingdom confirms the following :

The Manufacturer : INDIVIOR UK LIMITED

Site address : INDIVIOR UK LIMITED, DANSOM LANE, HULL, HU8 7DS, UNITED KINGDOM

Is an active substance manufacturer that has been inspected in accordance with Regulation 327 of The Human Medicines Regulations 2012 (SI 2012/1916).

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on 22/05/2025 , it is considered that it complies with

- The principles of GMP for active substances referred to in Regulation B17 and C17 of the Human Medicines Regulations 2012 (SI 2012/1916)

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. This certificate is valid only when presented with all pages and both Parts 1 and 2. The authenticity of this certificate may be verified in MHRA-GMDP. If it does not appear, please contact the issuing authority.

- *(1) Guidance on the interpretation of this template can be found in the Help menu of MHRA-GMDP database.*
- *(2) These requirements fulfil the GMP recommendations of WHO.*

Part 2

Human Medicinal Products

Manufacture of active substance. Names of substances subject to inspection :

- [2000008277] BUPRENORPHINE HYDROCHLORIDE
- [1000007171] BUPRENORPHINE

3. MANUFACTURING OPERATIONS - ACTIVE SUBSTANCES

BUPRENORPHINE HYDROCHLORIDE

3.1 Manufacture of Active Substance by Chemical Synthesis

	3.1.1 Manufacture Of Active Substance Intermediates
	3.1.2 Manufacture Of Crude Active Substance
	3.1.3 Salt Formation/Purification steps (eg. Crystallisation) API is precipitated by formation of hydrochloride salt using hydrogen chloride gas
3.5	General Finishing Steps
	3.5.1 Physical Processing Steps Product is dried under nitrogen / vacuum and then sieved
	3.5.2 Primary Packaging
	3.5.3 Secondary Packaging
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing

BUPRENORPHINE

3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture Of Active Substance Intermediates
	3.1.2 Manufacture Of Crude Active Substance
	3.1.3 Salt Formation/Purification steps (eg. Crystallisation) Purification & filtration of Stage 6R material
3.5	General Finishing Steps
	3.5.2 Primary Packaging
	3.5.3 Secondary Packaging
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing

Restrictions or Remarks

This certificate is issued based on a desk-based assessment of GMP compliance information provided by the manufacturer. This certificate should be used in combination with the relevant authorisation/registration. A risk-based site inspection programme remains in force

22/05/2025	Name and signature of the authorised person of the Competent Authority of United Kingdom Confidential Medicines and Healthcare products Regulatory Agency Tel : Confidential